Breaking News

BrainStorm, Mayo Clinic Enter ALS Trial Pact

By Kristin Brooks | January 29, 2014

To conduct Phase II trial of NurOwn in ALS

BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, has signed a definitive agreement with the Mayo Clinic in Rochester, MN to conduct its Phase II trial of NurOwn in amyotrophic lateral sclerosis (ALS). Mayo's Human Cell Therapy Lab will manufacture the NurOwn cells for the clinical trial. Additional sites for the multi-center trial include the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
"We are delighted to be progressing further with our preparations for the trial and honored to be collaborating with Professor Anthony Windebank and the Mayo Clinic," said Chaim Lebovits, president of BrainStorm. Mayo Clinic is one of the largest stem cell clinical trial centers worldwide, with 27 trials currently in Phase I.
"BrainStorm's mesenchymal stem cell-based approach is very compatible with some of the research conducted in our center," commented Anthony Windebank, M.D., professor of Neurology and Principal Investigator of the study. "This trial is a logical next step in developing novel treatments for ALS which is a terrible disease with no effective treatment for our patients and their families."

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research